Buscar
Mostrando ítems 1-10 de 33
Depletion of complement enhances the clearance of Brucella abortus in mice
(2018)
Brucellosis is a bacterial disease of animals and humans. Brucella abortus
barely activates the innate immune system at the onset of infection, and this
bacterium is resistant to the microbicidal action of complement. ...
Venomics of the poorly studied hognosed pitvipers Porthidium arcosae and Porthidium volcanicum
(2021)
We report the first proteomics analyses of the venoms of two poorly studied snakes, the Manabi hognosed pitviper Porthidium arcosae endemic to the western coastal province of Manabí (Ecuador), and the Costa Rican hognosed ...
Proteomic and toxicological analysis of the venom of Micrurus yatesi and its neutralization by an antivenom
(2022)
Coralsnakes belong to the family Elapidae and possess venoms which are lethal to humans and can be grouped based on the predominance of either three finger toxins (3FTxs) or phospholipases A2 (PLA2s). A proteomic and ...
Unresolved issues in the understanding of the pathogenesis of local tissue damage induced by snake venoms
(2018-06)
Snakebite envenoming by viperid species, and by some elapids, is characterized by a complex pattern of
tissue damage at the anatomical site of venom injection. In severe cases, tissue destruction may be so
extensive as ...
From Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy
(2016)
The snake is the symbol of medicine due to its association with Asclepius, the
Greek God of medicine, and so with good reasons. More than 725 species of venomous
snakes have toxins specifically evolved to exert potent ...
High-density peptide microarray exploration of the antibody response in a rabbit immunized with a neurotoxic venom fraction
(2017-11)
Polyvalent snakebite antivenoms derive their therapeutic success from the ability of their antibodies to
neutralize venom toxins across multiple snake species. This ability results from a production process
involving ...
Preclinical evaluation of the efficacy of antivenoms for snakebite envenoming: State-of-the-art and challenges ahead
(2017-05)
Animal-derived antivenoms constitute the mainstay in the therapy of snakebite envenoming. The efficacy of antivenoms to neutralize toxicity of medically-relevant snake venoms has to be demonstrated through meticulous ...
A myotoxic Lys49 phospholipase A2-homologue is the major component of the venom of Bothrops cotiara from Misiones, Argentina
(2018-04-27)
Bothrops cotiara is a pitviper found in Southeastern Brazil and, scarcely, in the Misiones province of Argentina. In contrast to considerable information available on the venom of the Brazilian snake population, that of ...
Phospholipase A2 myotoxins from Bothrops snake venoms
(1995-11)
The genus Bothrops is distributed over all Latin America, From Mexico to Argentina, and comprises nearly 31 species of snake. In most of these countries, Bothrops spp. cause the majority of snake bit envenomations, which ...
Antibody-dependent enhancement of toxicity of myotoxin II from Bothrops asper
(2024)
Improved therapies are needed against snakebite envenoming, which kills and
permanently disables thousands of people each year. Recently developed
neutralizing monoclonal antibodies against several snake toxins have ...